An interventional study of PRIME care and Usual care in Clinical High Risk Syndrome for Psychosis, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 12 Years to 30 Years. Per ClinicalTrials.gov, last updated 2019-05-28.
Sponsored by Yale University · Not applicable, Interventional, and Health services research
The purpose of this study is to determine whether specialty care is superior to usual care in the treatment of patients at clinical high risk for psychosis.
This study is a randomized clinical effectiveness trial for patients at clinical high risk for psychosis that compares two treatments: 1) specialty care delivered in a specialized clinical for patients at clinical high risk for psychosis versus 2) treatment as usual in the community.
Yale University is the lead sponsor of 1,763 studies on the registry; 292 are open to participants now.
Of its 217 completed or terminated interventional studies of FDA-regulated products, 128 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet all of the following:
Exclusion Criteria:
Subjects must not meet any of the following:
Specialized care in the PRIME clinic
Other: PRIME care
Usual care in the community
Other: Usual care
Specialist medication, cognitive behavior therapy, family-focused therapy
Medication and psychotherapy as available form community providers
Global Assessment of Functioning
Time frame: 24 months
Service utilization
hospitalizations and emergency room use
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.